| 1. |
|
|
| 2. |
- Aitken, Candice L., et al.
(författare)
-
Tumor localization and image registration of F-18FDG coincidence detection scans with computed tomographic scans
- 2002
-
Ingår i: Clinical Nuclear Medicine. - : Ovid Technologies (Wolters Kluwer Health). - 0363-9762 .- 1536-0229. ; 27:4, s. 275-282
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: The aim of this study was to determine the feasibility of registering routine clinical F-18 fluorodeoxyglucose (FDG) coincidence detection (CD) scans with computed tomographic (CT) scans for radiation treatment planning and case management. Methods: F-18 FDG CD and chest CT scans, performed in 10 randomly selected patients with confirmed or possible adenocarcinoma of the lung, were evaluated. The quality of the matches was verified by comparisons of the center-to-center distance between a region of interest (ROI) manually drawn on the CT slice and warped onto the CD slice with an ROI drawn manually directly on the CD slice. In addition, the overlap between the two ROIs was calculated. Results: All 10 F-18 FDG CD and CT scans were registered with good superimposition of soft tissue density on increased radionuclide activity. The center-to-center distance between the ROIs ranged from 0.29 mm to 8.08 mm, with an average center-to-center distance of 3.89 mm 2.42 mm (0.69 pixels +/- 0.34 pixels). The ROI overlap ranged from 77% to 99%, with an average of 90% +/- 5.6%. Conclusions: Although the use of F-18 FDG CD shows great promise for the identification of tumors, it shares the same drawbacks as those associated with radiolabeled monoclonal antibody SPECT and ligand-based positron emission tomographic scans in that anatomic markers are limited. This study shows that image registration is feasible and may improve the clinical relevance of CD images.
|
|
| 3. |
|
|
| 4. |
- Jokar, Narges, et al.
(författare)
-
Theranostic Approach in Breast Cancer A Treasured Tailor for Future Oncology
- 2021
-
Ingår i: Clinical Nuclear Medicine. - : Lippincott Williams & Wilkins. - 0363-9762 .- 1536-0229. ; 46:8, s. E410-E420
-
Tidskriftsartikel (refereegranskat)abstract
- Breast cancer is the most frequent invasive malignancy and the second major cause of cancer death in female subjects mostly due to the considerable diagnostic delay and failure of therapeutic strategies. Thus, early diagnosis and possibility to monitor response to the treatment are of utmost importance. Identification of valid biomarkers, in particular new molecular therapeutic targets, that would allow screening, early patient identification, prediction of disease aggressiveness, and monitoring response to the therapeutic regimen has been in the focus of breast cancer research during recent decades. One of the intensively developing fields is nuclear medicine combining molecular diagnostic imaging and subsequent (radio)therapy in the light of theranostics. This review aimed to survey the current status of preclinical and clinical research using theranostic approach in breast cancer patients with potential to translate into conventional treatment strategies alone or in combination with other common treatments, especially in aggressive and resistant types of breast cancer. In addition, we present 5 patients with breast cancer who were refractory or relapsed after conventional therapy while presumably responded to the molecular radiotherapy with Lu-177-trastuzumab (Herceptin), Lu-177-DOTATATE, and Lu-177-FAPI-46.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Mathies, Franziska L., et al.
(författare)
-
The Early Perfusion Image Is Useful to Support the Visual Interpretation of Brain Amyloid-PET With 18F-Flutemetamol in Borderline Cases
- 2024
-
Ingår i: CLINICAL NUCLEAR MEDICINE. - 0363-9762 .- 1536-0229. ; 49:9, s. 838-846
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: Visual interpretation of brain amyloid-beta (A beta) PET can be difficult in individuals with borderline A beta burden. Coregistration with individual MRI is recommended in these cases, which, however, is not always available. This study evaluated coregistration with the early perfusion frames acquired immediately after tracer injection to support the visual interpretation of the late A beta-frames in PET with F-18-flutemetamol (FMM). Patients and Methods: Fifty dual-time-window FMM-PET scans of cognitively normal subjects with 0 to 60 Centiloids were included retrospectively (70.1 +/- 6.9 years, 56% female, MMSE score 28.9 +/- 1.3, 42% APOE epsilon 4 carrier). Regional A beta load was scored with respect to a 6-point Likert scale by 3 independent raters in the 10 regions of interest recommended for FMM reading using 3 different settings: A beta image only, A beta image coregistered with MRI, and A beta image coregistered with the perfusion image. The impact of setting, within- and between-readers variability, region of interest, and A beta-status was tested by repeated-measure analysis of variance of the Likert score. Results: The Centiloid scale ranged between 2 and 52 (interquartile range, 7-19). Support of visual scoring by the perfusion image resulted in the best discrimination between A beta-positive and A beta-negative cases, mainly by improved certainty of excluding A beta plaques in A beta-negative cases (P = 0.030). It also resulted in significantly higher between-rater agreement. The setting effect was most pronounced in the frontal lobe and in the posterior cingulate cortex/precuneus area (P = 0.005). Conclusions: The early perfusion image is a suitable alternative to T1-weighted MRI to support the visual interpretation of the late A beta image in FMM-PET.
|
|
| 8. |
- Moy, Linda, et al.
(författare)
-
Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans
- 2007
-
Ingår i: Clinical Nuclear Medicine. - Philadephia, Pennsylvania, USA : Lippincott Williams & Wilkins. - 0363-9762 .- 1536-0229. ; 32:3, s. 194-198
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: This study compared prone acquisition of PET scans with traditional supine acquisition to improve fusion of PET scans with MRI scans and improve evaluation of enhancing breast lesions detected on MRI. Materials and Methods: MRI breast scans are acquired in the prone position using a breast coil to allow the breasts to hang pendant. An apparatus was fabricated to allow prone acquisition of PET scans. Fused scans from 2 patients acquired both prone and supine were contrasted with those from 3 patients acquired supine only. All 5 MRI scans were acquired on standard scanners. The PET scans were acquired with a PET/CT unit using a low-dose CT scan for attenuation correction. The PET and MRI volumes were matched twice (using a semiautomated registration method) by different operators. The additional value of fusion was judged using reports from the original (nonfused) MRI and PET, joint rereading of the volumes side by side, and examination of fused images. Results: Of 12 enhancing lesions on breast MRI, 7 demonstrated uptake on PET/CT. In the 3 supine-only cases, the fused images were not interpretable because of the marked distortion of the breasts. In the 2 prone cases, the fused images increased our confidence in characterizing a lesion as benign or malignant. Interpretations were confirmed by clinical follow up in 2 or histologic results in 3 patients. Conclusions: PET MRI fusion is feasible and may assist in localizing lesions detected on either study. A more extensive study is under-way to confirm the value of this fusion technique.
|
|
| 9. |
- Ozden, C., et al.
(författare)
-
FDG Uptake in the Basal Forebrain as Measured by Digital High-Resolution PET Is a Promising Marker of Basal Forebrain Degeneration in the Lewy Body Disease Spectrum A Pilot Study
- 2020
-
Ingår i: Clinical Nuclear Medicine. - : Ovid Technologies (Wolters Kluwer Health). - 0363-9762 .- 1536-0229. ; 45:4, s. 261-266
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose Cognitive decline in diseases of the Lewy body spectrum (LBS) is linked to dysfunction/degeneration of the basal forebrain (BF). Assessment of glucose metabolism in the BF by FDG PET is hampered by the small size of the BF and limited spatial resolution of conventional PET. This pilot study tested the feasibility of assessing BF glucose metabolism by high-resolution digital PET (dPET). Patients and Methods The retrospective study included 12 LBS patients (61-86 years, 5 demented). Whole-brain stereotactic normalization to anatomical standard space was followed by local stereotactic normalization of a 7 x 7 x 7-cm(3) box around the BF to a custom-made 1 x 1 x 1-mm(3) FDG dPET template. FDG uptake was scaled voxelwise to mean FDG uptake in the pons. Scaled FDG uptake in the BF was compared between demented and nondemented LBS patients and tested for correlation with cortical FDG uptake. Results Scaled FDG uptake in the BF was significantly lower in demented compared with nondemented patients (1.14 +/- 0.09 vs 1.25 +/- 0.06, P = 0.031). Brain-wide voxel-based testing for correlations with scaled FDG uptake in the BF revealed a large cluster comprising medial and ventrolateral frontal cortex, anterior cingulate cortex, insular cortex, and striatum as well as smaller clusters in motor cortex and occipital cortex (P < 0.001, uncorrected). Conclusions These results suggest that dementia-associated BF degeneration in LBS can be sensitively measured as reduced BF FDG uptake on dPET. More accurate delineation of the BF based on individual high-resolution MRI might be useful to make optimal use of improved spatial resolution of dPET and to correct for possible disease- and age-dependent partial volume effects.
|
|
| 10. |
- Rottenburger, Christof, et al.
(författare)
-
A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy—68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation
- 2018
-
Ingår i: Clinical Nuclear Medicine. - 0363-9762 .- 1536-0229. ; 43:4, s. 252-255
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Glucagonoma is an extremely rare, glucagon-secreting neuroendocrine tumor of the pancreas. Only sparse data are available about the characteristics of this tumor in somatostatin receptor imaging and only for the situation of initial diagnosis. We present a series of 3 glucagonoma patients who underwent at least 1 68Ga-DOTATATE PET/CT scan. All patients were diagnosed by either histology and/or elevated serum levels of glucagon. The presented cases suggest that somatostatin receptor–based imaging can probably be used for re-evaluation of disease status in patients with glucagonoma in a similar way as it is already established for neuroendocrine tumors of other origin.
|
|
